The KIF5B Knockout NCI-H1975 Polyclonal Cells product provides a heterogeneous CRISPR/Cas9-edited population of NCI-H1975 lung adenocarcinoma cells with disrupted KIF5B gene expression. This polyclonal knockout model enables loss-of-function analysis of the kinesin-1 heavy chain in a genetically diverse cell pool, preserving the parental EGFR L858R/T790M mutations while eliminating functional KIF5B protein.
The host NCI-H1975 line, derived from a female non-smoker with non-small cell lung adenocarcinoma, carries EGFR L858R and T790M mutations, serving as a key in vitro model for EGFR-mutant NSCLC and resistance to first-generation tyrosine kinase inhibitors. Its established use in drug screening, especially with osimertinib, and its well-defined signaling properties facilitate detailed mechanistic studies.
KIF5B encodes the kinesin-1 heavy chain, a microtubule motor protein that transports mitochondria, endosomes, and organelles. Its function is coordinated by adaptors TRAK1, TRAK2, Miro1 (RHOT1), and Miro2 (RHOT2), along with kinesin light chain KLC1, and is regulated by GSK3?? phosphorylation. This motile network drives mitochondrial positioning, EGFR endosomal recycling, mitotic spindle organization, and MTORC1 signaling, linking motor activity to cellular energetics and signal transduction.
In NCI-H1975 cells, KIF5B loss impairs microtubule-based mitochondrial trafficking and EGFR endosome recycling, resulting in aberrant mitochondrial distribution, reduced EGFR surface expression, and diminished downstream AKT and ERK signaling. This attenuation of oncogenic pathways curtails proliferation and may sensitize cells to EGFR inhibitors like osimertinib, highlighting the dependency of EGFR-driven cancer on coordinated intracellular transport. The model thus illuminates how motor protein disruption can influence drug response in lung adenocarcinoma.
These polyclonal knockout cells are applicable to quantitative assays for mitochondrial dynamics (immunofluorescence), EGFR recycling (biotin-based recycling assay), proliferation (MTT), and drug sensitivity (osimertinib titration). Molecular analyses include Western blotting for KIF5B and phospho-EGFR/AKT/ERK, RT-qPCR, mitochondrial ATP quantification, and flow cytometric apoptosis detection. The population heterogeneity supports functional genomics screens to uncover synthetic lethal interactions and trafficking-modulated resistance mechanisms. For further inquiries, contact Ascent Research.
